{"doi":"10.1016/j.cell.2024.12.010","title":"Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients","abstract":null,"journal":"Cell","year":2025,"id":624257,"datarank":0.6798899239729885,"base_score":4.532599493153256,"endowment":4.532599493153256,"self_citation_contribution":0.6798899239729885,"citation_network_contribution":0.0,"self_endowment_contribution":0.6798899239729885,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":92,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1215629,"name":"Lu Gan","orcid":"0000-0003-1056-7660","position":1,"is_corresponding":false},{"id":687021,"name":"Bing Wang","orcid":"0000-0002-9647-5275","position":2,"is_corresponding":false},{"id":772561,"name":"Tao Wu","orcid":"0000-0003-0766-3643","position":3,"is_corresponding":false},{"id":432497,"name":"Fei Yao","orcid":"0000-0002-1769-9140","position":4,"is_corresponding":false},{"id":165319,"name":"Wenlin Gong","orcid":null,"position":5,"is_corresponding":false},{"id":978123,"name":"Hongmei Peng","orcid":"0000-0001-7214-5995","position":6,"is_corresponding":false},{"id":1613651,"name":"Zhiming Deng","orcid":null,"position":7,"is_corresponding":false},{"id":1613653,"name":"Guoyou Xiao","orcid":null,"position":8,"is_corresponding":false},{"id":1382984,"name":"Xiyu Liu","orcid":"0000-0002-6803-2696","position":9,"is_corresponding":false},{"id":1613654,"name":"Jintong Na","orcid":null,"position":10,"is_corresponding":false},{"id":1613655,"name":"Desong Xia","orcid":null,"position":11,"is_corresponding":false},{"id":1140025,"name":"Xianjun Yu","orcid":"0000-0002-6697-7143","position":12,"is_corresponding":false},{"id":1024502,"name":"Zhikun Zhang","orcid":"0000-0002-0945-7176","position":13,"is_corresponding":false},{"id":1613656,"name":"Bangde Xiang","orcid":null,"position":14,"is_corresponding":false},{"id":437329,"name":"Yu Huo","orcid":"0000-0002-9504-0018","position":15,"is_corresponding":false},{"id":89720,"name":"Dan Yan","orcid":"0000-0003-2985-3798","position":16,"is_corresponding":false},{"id":1613657,"name":"Zhixin Dong","orcid":null,"position":17,"is_corresponding":false},{"id":376380,"name":"Fang Fang","orcid":"0000-0002-1805-2031","position":18,"is_corresponding":false},{"id":316193,"name":"Yun Ma","orcid":null,"position":19,"is_corresponding":false},{"id":1613658,"name":"Guanqiao Jin","orcid":null,"position":20,"is_corresponding":false},{"id":1613659,"name":"Danke Su","orcid":null,"position":21,"is_corresponding":false},{"id":651199,"name":"Xiuli Liu","orcid":"0000-0001-5791-2017","position":22,"is_corresponding":false},{"id":211885,"name":"Qiang Li","orcid":null,"position":23,"is_corresponding":false},{"id":1613660,"name":"Hai Liao","orcid":null,"position":24,"is_corresponding":false},{"id":873742,"name":"Chao Tang","orcid":"0000-0002-5072-5849","position":25,"is_corresponding":false},{"id":648088,"name":"Jian He","orcid":"0000-0003-3846-3038","position":26,"is_corresponding":false},{"id":1613661,"name":"Zhiping Tang","orcid":null,"position":27,"is_corresponding":false},{"id":1613662,"name":"Shilai Zhang","orcid":null,"position":28,"is_corresponding":false},{"id":1613663,"name":"Bingqing Qiu","orcid":null,"position":29,"is_corresponding":false},{"id":1090347,"name":"Zhi Yang","orcid":"0000-0002-2222-2312","position":30,"is_corresponding":false},{"id":1402940,"name":"Lihui Yang","orcid":"0009-0005-1261-1444","position":31,"is_corresponding":false},{"id":1613664,"name":"Ziqin Chen","orcid":null,"position":32,"is_corresponding":false},{"id":1613665,"name":"Mengsi Zeng","orcid":null,"position":33,"is_corresponding":false},{"id":1613666,"name":"Ronghua Feng","orcid":null,"position":34,"is_corresponding":false},{"id":1613667,"name":"Jiege Jiao","orcid":null,"position":35,"is_corresponding":false},{"id":1486331,"name":"Yuan Liao","orcid":"0000-0001-8268-6947","position":36,"is_corresponding":false},{"id":1613668,"name":"Tinghua Wang","orcid":null,"position":37,"is_corresponding":false},{"id":849614,"name":"Liangliang Wu","orcid":"0000-0003-4771-2833","position":38,"is_corresponding":false},{"id":1613669,"name":"Zhengcheng Mi","orcid":null,"position":39,"is_corresponding":false},{"id":1613670,"name":"Ziqun Liu","orcid":null,"position":40,"is_corresponding":false},{"id":305526,"name":"Si Shi","orcid":"0000-0002-6652-0629","position":41,"is_corresponding":false},{"id":683443,"name":"Kun Zhang","orcid":"0000-0001-8915-1769","position":42,"is_corresponding":false},{"id":923727,"name":"Wei Shi","orcid":"0000-0002-2236-4708","position":43,"is_corresponding":false},{"id":556371,"name":"Yongxiang Zhao","orcid":"0000-0003-2214-5887","position":44,"is_corresponding":false},{"id":1380862,"name":"Liping Zhong","orcid":"0009-0008-3344-523X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients","abstract":"Recently, oncolytic virus (OV) therapy has shown great promise in treating malignancies. However, intravenous safety and inherent lack of immunity are two significant limitations in clinical practice. Herein, we successfully developed a recombinant Newcastle disease virus with porcine α1,3GT gene (NDV-GT) triggering hyperacute rejection. We demonstrated its feasibility in preclinical studies. The intravenous NDV-GT showed superior ability to eradicate tumor cells in our innovative CRISPR-mediated primary hepatocellular carcinoma monkeys. Importantly, the interventional clinical trial treating 20 patients with relapsed/refractory metastatic cancer (Chinese Clinical Trial Registry of WHO, ChiCTR2000031980) showed a high rate (90.00%) of disease control and durable responses, without serious adverse events and clinically functional neutralizing antibodies, further suggesting that immunogenicity is minimal under these conditions and demonstrating the feasibility of NDV-GT for immunovirotherapy. Collectively, our results demonstrate the high safety and efficacy of intravenous NDV-GT, thus providing an innovative technology for OV therapy in oncological therapeutics and beyond.","is_dataset_classified":null,"base_score":4.5217885770490405,"endowment":4.5217885770490405,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39826543","pmcid":null,"openalex_id":"https://openalex.org/W4406509375","authors":[],"funders":[],"total_grants":0,"fwci":85.401,"citation_percentile":0.99964301,"influential_citations":0,"citation_trend":[{"year":2025,"count":48},{"year":2026,"count":43}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.1016/j.cell.2024.12.010","host_type":"journal"},{"url":"https://doi.org/10.1016/j.cell.2024.12.010","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0092867424014235?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0092867424014235?httpAccept=text/plain","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39826543","host_type":"repository"}],"fields_of_study":["Virus-based gene therapy research","Viral Infectious Diseases and Gene Expression in Insects","CAR-T cell therapy research"],"mesh_terms":["Adult","Aged","Animals","Female","Carcinoma, Hepatocellular","Humans","Liver Neoplasms","Male","Middle Aged","Neoplasms","Newcastle disease virus","Swine","Cell Line, Tumor","Oncolytic Virotherapy","Oncolytic Viruses","Mice"],"keywords":["Oncolytic virus","Biology","Refractory (planetary science)","Cancer","Virus","Clinical trial","Virology","Cancer research","Bioinformatics","Safety","Hyperacute rejection","Recombinant Newcastle disease virus","efficacy","Immunovirotherapy","Α1,3gt","Refractory Cancer","Crispr Monkey Liver Cancer Model","Intravenous Ndv"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T03:12:48.127717Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}